Daniel Hetu

Daniel Hetu is currently a Managing Director at Lumira Capital Investment Management, Inc. He also holds director positions at Gladius Pharmaceuticals, Inc., Gladius Pharmaceuticals Corp., Xylocor Therapeutics, Inc., Kisoji Biotechnology, Inc., Transposon Therapeutics, Inc., Specific Biologics, Inc., Congruence Therapeutics, Inc., and is an Executive Vice President at LAVA Medtech Acquisition Corp.
In the past, Dr. Hetu has worked as a Director at Cardiac Dimensions, Inc., Resonant Medical, Inc., U-Systems, Inc., Réseau Capital, IMV, Inc., Thrasos Therapeutics, Inc., and Opsens Medical.
He was also a Director and Vice President at OsteoqQC, Inc. from 2014 to 2022.
Additionally, he held positions as Vice President of Corporate Development at Biochem Pharma, Inc. and Vice President of Business Development at Shire Pharmaceuticals, Inc.Dr. Hetu holds a doctorate degree from the University of Sherbrooke and an MBA from École des Hautes Études Commerciales de Paris.